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Abstract
Objectives: South-Asians have lower adiponectin levels compared to Caucasians. It was not clear
however, if this intrinsic feature is related to aspects of glucose metabolism. This study aims to
determine the relationship between body fat distribution and adipocytokine in South-Asian subjects
by measuring serum adipocytokines, adiposity, insulinemia, and glucose tolerance levels.
Methods: In this cross-sectional study, 150 South-Asians (80 males, 70 females) were included, 60
had NGT (Control group, Age 51.33 ± 11.5, BMI 27 ± 2.3), 60 had IGT (Age 57.7 ± 12.5, BMI 27.2
± 2.7), 30 had type 2 DM (Age 49.5 ± 10.9, BMI 28 ± 1.7). Measures of adiposity, adipocytokines
and other metabolic parameters were determined. Parameters were measured using the following:
a) Plasma glucose by glucose oxidase method b) CRP by immunoturbidimetric method (Roche/
Hitachi analyser) c) insulin by Medgenix INS-ELISA immunoenzymetric assay by Biosource
(Belgium) d) Leptin, Adiponectin by radioimmunoassay kits by Linco Research (St. Charles MO) e)
Resistin by immunoassay kits by Phoenix Pharmaceuticals INC (530 Harbor Boulevard, Belmont
CA 94002, USA).
Results: Adiponectin concentrations were highest in NGT, decreased in IGT and lowest in DMT2,
(both p < 0.01). Leptin was significantly higher in DMT2 than IGT and NGT p = 0.02 and 0.04
respectively. There was a significant positive relationships between log adiponectin and 2-hr insulin
values, p = 0.028 and history of hypertensions and a ischemic heart disease p = 0.008 with R = 0.65.
There was a significant inverse correlation between log adiponectin and resistin, p < 0.01.
Conclusion: Resistin levels had an inverse correlation with adiponectin levels, indicating an inverse
relationship between pro-inflammatory cytokines and adiponectin. Adiponectin levels were related
to glucose tolerance.
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The association between excess adipose tissue and the
development of type 2 diabetes, dyslipidaemia and cardi-
ovascular disease has long been recognised. It is now
established that adipose tissue is a significant endocrine
organ of humans that secretes over 30 proteins many of
which have actions on the processes of fat accumulation
and metabolism. Numerous studies have attempted to
identify several mechanisms linking obesity with insulin
resistance and type 2 diabetes, and factors have been sug-
gested to play in obesity-related insulin resistance such as
tumour necrosis factor-α(TNF-α), interleukin-6 (IL-6),
non-esterified fatty acids (NEFA), resistin and adiponectin
[1]. Adiponectin, the gene product of the adipose most
abundant gene transcript 1 (apM1) [2], is a collagen-like
protein that is exclusively synthesized in white adipose tis-
sue and has been postulated to have an important role in
the modulation of glucose and lipid metabolism in insu-
lin-sensitive tissues both in humans and animals. Circu-
lating adiponectin concentrations are decreased in obese
[3] and type 2 diabetes [4] and the reduction is believed
to have a role in the pathogenesis of cardiovascular dis-
eases associated with obesity and other components of
the metabolic syndrome [5-7]. Recent evidence has also
suggested the role of adiponectin in the regulation of insu-
lin action, energy homeostasis, obesity and insulin resist-
ance. Circulating adiponectin levels and adiponectin gene
expression in adipose tissue are reduced in patients with
type 2 diabetes [8-10]. Available data suggest that adi-
ponectin might reduce hepatic glucose production and
increase muscle glucose utilisation, perhaps by increasing
fat oxidation and thereby reducing circulating NEFA levels
and intramyocellular accumulation [11]. Studies of adi-
pocytokines in populations with different propensity for
obesity, insulin resistance, type 2 diabetes and atheroscle-
rosis are needed and South-Asians are interesting in this
respect, because they have very high incidence of insulin
resistance, central obesity, type 2 diabetes and cardiovas-
cular disease [12-17]. In a previous study by Valsmakis et
al [18], South-Asians have lower adiponectin levels com-
pared to Caucasians. It was not clear however, if this fea-
ture of the South-Asians is related to aspects of glucose
metabolism. This study aims to determine the relation-
ship between body fat distribution and adipocytokines in
South-Asian subjects by measuring serum adiponectin,
resistin, and leptin, measures of adiposity, insulinemia
and glucose tolerance levels.
Subjects and methods
In this cross sectional study, 150 subjects (80 males, 70
females), all South-Asians were studied, the patients were
matched for BMI, and there were 60 subjects with NGT
(Non-diabetic control group), 60 subjects with IGT and
30 with DM. The ethics approval was taken from East Bir-
mingham Hospital local ethical committee. The patients
were recruited from community gatherings and were
invited to the hospital.
Clinical assessment
This included height, weight, body mass index, waist and
hip circumference and sagittal diameter. The Holtain
Khan abdominal caliper by Holtain Ltd. (Crymych, UK)
was used to measure sagittal abdominal diameter. Each
patient was examined supine on a firm examination table.
Using sliding callipers with parallel blades a direct reading
can be made between its lower arm (touching the subjects
back) and its sliding upper arm (touching the front of the
subjects abdomen). Tanita fat monitoring machine by
Tanita UK Ltd. (Yiewsley, Middlesex UB7 7RY, UK)was
used to measure body fat percentage and lean body mass,
with the patient standing bare footed on the machine,
which calculated these parameters.
Laboratory measurements and analytical procedures
The patients were requested to come to the hospital fast-
ing and had baseline bloods done with the serum saved
for analysis. They had a standard 2 hr oral glucose toler-
ance test done along with the measurements of fasting
and 2 hr insulin. Plasma glucose was measured using glu-
cose oxidase method, while high sensitive C-reactive pro-
tein was measured using immunturbidimetric method
(Roche/Hitachi analyser). Insulin was determined using
the Medgenix-INS-ELISA immunoenzymetric assay by
Biosource-Europe S.A. (B-1400 Nivelles, Belgium) [19].
Serum leptin and adiponectin were measured using the
radio-immunoassay (RIA) commercially available kit by
Linco Research (St Charles MO-63304-USA) [20]. Serum
resistin was measured using the enzyme immunoassay kit
by Phoenix pharmaceuticals INC (530 Harbor Boulevard,
Belmont, CA 94002, USA [21]. Human resistin sensitivity
is 4 ng/ml with interassay and between assays variability
of <14% and <5% respectively.
Statistical analysis
Data were analysed using the Statistical Package for the
Social Sciences (SPSS for Windows, version 10). Data are
expressed as mean (standard deviation) or as median and
range if not normally distributed. Leptin and adiponectin
values were logarithmically transformed to normalise the
data. Groups were compared by student's unpaired t-test
or one-way ANOVA was used for inter-group comparisons
with normally distributed data and if not normally dis-
tributed, by the Mann Whitney U test. Simple and partial
correlation coefficients between the variables were deter-
mined and multiple regression analysis was done to deter-
mine relationships between variables of interest.
Results
A total of 150 subjects all South-Asians were studied, (80
males,70 females), 60 subjects had normal glucose toler-Page 2 of 5
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newly diagnosed type 2 diabetes. The baseline characteris-
tics are shown in table 1. The BMI matched subjects in the
three groups, were similar in anthropometric measure-
ments and fat topography. There was no significant differ-
ence with respect to percentage body fat, waist
circumference, hip circumference and sagittal diameter.
There was a statistically significant difference observed
with respect to 2-hr insulin level, which was highest in the
IGT group and lowest in patients with NGT, a reflection of
the change in beta cell function across the glycaemic spec-
trum. Also CRP and HOMIR were higher in DM patient
than NGT p = 0.02 and 0.04 respectively. Adiponectin
concentrations were highest in subjects with NGT but
decreased in subjects with IGT and lowest in type 2 diabet-
ics, (both p < 0.01. (Fig 1). Leptin concentration was sig-
nificantly higher in DM than IGT and NGT p = 0.02 and
0.04 respectively. We examined the relationship of log
adiponectin with other adipocytokines cross the spectrum
of glycaemia, and also other parameters presented in
Table 1 like insulin resistance and inflammatory markers
like CRP. When adiponectin was used as a dependent var-
iable there was a significant positive relationships with 2-
hr insulin values, p = 0.028 and history of hypertensions
and ischemic heart disease p = 0.008 with R = 0.65. There
was a significant inverse correlation between log adi-
ponectin and resistin, p < 0.01.
We also compared subjects with NGT, IGT and type2 dia-
betes to see the effect of change in glucose tolerance on
adiponectin levels, and what effect if any this has on other
adipocytokines. The adiponectin levels decreased across
the glycaemic spectrum from NGT to type 2 diabetes.
There was a significant decrease in the levels of adiponec-
tin between the NGT and IGT subjects, p < 0.05, similarly
there were differences between NGT and DM subjects, p <
0.05. The decrease between IGT and DM was not statisti-
cally significant. The resistin levels increased across the
glycaemic levels, the results were statistically significant
between NGT and IGT subjects, p < 0.05 though this dif-
ference was not statistically significant between NGT and
DM subjects.
Discussion
In a previous study it was shown that adiponectin concen-
trations were significantly lower in the South-Asians when
compared to Caucasians [18]. In recent study, subjects
with type 2 diabetes and impaired glucose tolerance test
showed significantly decreased serum adiponectin con-
centrations. Although serum adiponectin levels were neg-
atively correlated with BMI, diabetic subjects had lower
values of serum adiponectin than did non-diabetic sub-
jects, independent of the BMI [8,22,23]. Weyer et al,
showed that serum adiponectin concentrations were more
closely related to fasting insulinemia and to the rate of
insulin-stimulated glucose disposal, a direct measure of
insulin sensitivity, than to percent body fat and the 2-hr
glucose concentration suggesting that hyperinsulinaemia
and/or insulin resistance might be a major determinants
of the hypoadiponectinemia in obesity and type 2 diabe-
tes. One of possible mechanisms for this that has been
suggested is, overproduction of TNF-αby adipose tissue
[24-26]. Also in the recent study showed AdipoR1/R2
appears to be inversely regulated by insulin in physiolog-
ical and pathophysiological states such as fasting/refeed-
ing, insulin deficiency, and hyper-insulinemia models via
the insulin/phosphoinositide 3-kinase/Foxo1 pathway
and is correlated with adiponectin sensitivity[27]. Adi-
Table 1: Physical and metabolic characteristics of the study population (mean ± SD). NGT IGT DM
NGT IGT DM
Age 51.33 ± 11.5 57.7 ± 12.5* 49.5 ± 10.9
BMI (kg/m 2) 27 ± 2.3 27.2 ± 2.7 28 ± 1.7
Percent body fat 26.4 ± 4.9 27.2 ± 5.6 22.8 ± 2.3
Waist Circumference (cm) 96.6 ± 18.1 101 ± 9.4 102.4 ± 8.2
Hip Circumference (cm) 100.8 ± 17.9 103.6 ± 7.4 106.8 ± 7.1
Sagittal Diameter (cm) 24.4 ± 3.0 24.1 ± 3.8 25.5 ± 2.7
C-reactive protein # 3.5(0.4–18) 4.1(0.4–17) 6.1(0.8–13)*1
Adiponectin (µg/ml) # 18.7(1.5–65.6) 15.2(2.5–81.6)* 12.2(1.2–37.5)*1
Resistin (ng/ml) # 2.9(1.3–2.7) 3.7(1.4–6.1) 3.2(1.5–12.5)
Leptin (ng/ml) # 2.2(1.7–46.7) 10.1(2.8–34.3) 14.5(3.7–39.6)*2
Fasting insulin (pmol/L) 14 ± 9.7 16.8 ± 23.3 15.1 ± 6.5
2-hr Insulin (pmol/L) 72.1 ± 53 132.6 ± 54.5** 97.4 ± 78.7**
Fasting Glucose (mmol/L) 5.1(0.7) 5.7(1.1) 7.9(2.3)
30 min glucosa (mmol/L) 8.5 (1.5) 10.1 (1.5) 12.3 (1.7) **
2 h glucosa (mmol/L) 5.8 (1.1) 9.3 (1.6) 15.1 (3.7) **
HOMIR# 4.8 (1.1–40.1) 3.8 (1.3–24.5) 4.9 (1.9–8.7) *2
*p = 0.03, *p = 0.022, *p = 0.04 ** p < 0.001 compared to the NGT. All data presented in mean (SD) except # at median (Range)Page 3 of 5
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cells [28]. Decreased serum adiponectin may play a caus-
ative role in the development of insulin resistance.
In the present study in BMI matched South-Asian subjects,
we found that adiponectin concentration decrease across
the glycaemic spectrum, with NGT subjects having the
highest and subjects with type 2 diabetes the lowest con-
centrations. There is a significant decrease in the adi-
ponectin concentrations even at the stage of IGT. In a
different study it was found that serum adiponectin con-
centrations are lower in nondiabetic Pima Indians than in
Caucasians and in subjects with IGT and diabetes com-
pared with those with NGT, this indicates that factors
other than adiposity must play a role in determining adi-
ponectinemia [9]. In our study serum adiponectin levels
were negatively correlated with 2-hr plasma insulin con-
centration, though there was no relation with percentage
body fat. Circulating adiponectin levels have been shown
to decrease in parallel with progression of insulin resist-
ance during development of type 2 diabetes in rhesus
monkeys genetically predisposed to develop insulin
resistance [29]. In this study, there was a negative correla-
tion of adiponectin levels with body weight and fasting
insulin levels and a positive correlation with insulin-stim-
ulated glucose up-take (a marker of insulin sensitivity). In
these monkeys, the decline in adiponectin levels preceded
overt hyperglycaemia. Development of hyperinsulinae-
mia is one possible mechanism for the suppression of adi-
ponectin levels seen in this study. However,
hyperinsulinaemia per se seems unlikely as a mediator of
low adiponectin levels, since adiponectin levels remain
low in the later stage of type 2 diabetes in association with
decreased insulin levels. Adipocyte insulin action or signal
transduction rather than absolute levels of insulin may
regulate adiponectin concentration. In support of this
contention, Bogan and Lodish [30] have shown that secre-
tion of adiponectin by 3T3-L1 adipocytes requires phos-
patidylinositol 3-kinase (PI-3K), a major intermediate of
insulin signalling activity. Insulin stimulated insulin
receptor substrate 1 (IRS-1) associated PI-3K activity has
been shown to be decreased in adipocytes of type 2 dia-
betic subjects [31]. Thus it is possible that the decreased
adipocyte PI-3K activity in type 2 diabetic patients may
contribute to the decreased adiponectin levels. Other
investigators have presented data on the potential inverse
relationship between adiponectin and insulin action. Eug-
lycemic hyperinsulinaemia clamp studies both in human
and rats [32] have shown that insulin infusion leads to
decreased circulating adiponectin levels, consistent with
the interpretation that insulin exerts an acute effect on
adipocytes to decrease production and/or secretion of this
adipocytokines. Also some studies showed a relation
between the adiponectin and Coronary heart disease risk
factors, these results collectively indicate that plasma HDL
cholesterol levels and visceral fat masses are independ-
ently associated with plasma adiponectin concentra-
tions[33]. In another study a reduction in serum
adiponectin level is associated with the prevalence and
magnitude of systemic atherosclerosis including IHD and
ASO[34] which confirmed our finding in the South Asian
subjects.
In our study there was a significant increase in the resistin
levels between NGT and IGT subjects though there was no
statistically significant difference between NGT and DM
subjects. The negative correlation between serum resistin
and adiponectin levels may also suggest that, resistin
could be a marker for TNF-α which has been shown to be
associated with chronic inflammation and insulin resist-
ance. Previous studies have provided evidence for the
association of leptin with key variables of the metabolic
syndrome and with insulin sensitivity, independently of
obesity [35]. Several recent studies have documented a
relationship between leptin and insulin levels or insulin
sensitivity [36-38]. However, given the close correlation of
leptin with indices of adipose tissue mass, no studies were
able to investigate if leptin relates to those variables
through obesity and/or hyperinsulinaemia, or independ-
ent of them. In our study we could not elucidate any rela-
tionship between leptin levels according to glucose
tolerance.
Taken together, our findings indicate that the observed
changes in adiponectin are likely to be related to meta-
bolic changes associated with progression to diabetes. In
this study in a British South-Asian population with a high
incidence of type 2 diabetes, cardiovascular disease, cen-
tral obesity and metabolic syndrome, we have demon-
strated that serum adiponectin levels are inversely
correlated across the glycaemic spectrum with patients of
type 2 diabetes having the lowest levels. Even in patients
with IGT the serum adiponectin levels were lower than
BMI matched NGT subjects. Adiponectin concentration
was also negatively correlated with 2-hr plasma insulin
levels; these are consistent with the interpretation that
insulin exerts an acute effect on adipocytes to decrease
production and/or secretion of this adipocytokines.
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